LCMV GP (61-80)

LCMV GP (61-80) is a peptide fragment derived from lymphocytic choriomeningitis virus (LCMV) glycoprotein (GP), and corresponds to amino acids 61-80. LCMV GP (61-80) is a specific epitope which can induce CD4+ T-cell response[1][2][3].

Product Specifications

CAS Number

[232598-19-5]

UNSPSC

12352209

Target

Arenavirus

Type

Peptides

Related Pathways

Anti-infection

Applications

COVID-19-anti-virus

Field of Research

Infection; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/lcmv-gp-61-80.html

Purity

99.80

Solubility

H2O : 0.71 mg/mL (ultrasonic)

Smiles

OC(C=C1)=CC=C1C[C@@H](C(N[C@@H](CCCCN)C(NCC(N[C@@H](C(C)C)C(N[C@H](C(N[C@@H](CCC(N)=O)C(N[C@H](C(N[C@@H](CCCCN)C(N[C@@H](CO)C(N[C@@H](C(C)C)C(N[C@@H](CCC(O)=O)C(N[C@H](C(N[C@H](C(O)=O)CC(O)=O)=O)CC2=CC=CC=C2)=O)=O)=O)=O)=O)CC3=CC=CC=C3)=O)=O)CC4=CC=C(C=C4)O)=O)=O)=O)=O)NC([C@H]([C@@H](C)CC)NC([C@H](CC(O)=O)NC([C@H]5N(CCC5)C(CNC([C@H](CCCCN)NC([C@H](CC(C)C)NC(CN)=O)=O)=O)=O)=O)=O)=O

Molecular Formula

C108H160N24O31

Molecular Weight

2290.60

References & Citations

[1]Rodriguez F, et, al. CD4 (+) T cells induced by a DNA vaccine: immunological consequences of epitope-specific lysosomal targeting. J Virol. 2001 Nov; 75 (21) : 10421-30.|[2]Andargachew R, et, al. CD4 T Cell Affinity Diversity Is Equally Maintained during Acute and Chronic Infection. J Immunol. 2018 Jul 1; 201 (1) :19-30.|[3]Homann D, et, al. Mapping and restriction of a dominant viral CD4+ T cell core epitope by both MHC class I and MHC class II. Virology. 2007 Jun 20; 363 (1) : 113-23.|[4]Hilpert C, et al. Dendritic Cells Are Dispensable for T Cell Priming and Control of Acute Lymphocytic Choriomeningitis Virus Infection. J Immunol. 2016 Oct 1;197 (7) :2780-6.|[5]Siracusa F, et al. Nonfollicular reactivation of bone marrow resident memory CD4 T cells in immune clusters of the bone marrow. Proc Natl Acad Sci U S A. 2018 Feb 6;115 (6) :1334-1339.